High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A

Autor: Huaqin Sun, Xi Yang, Duolan Naren, Wenming Xu, Tianyou Yan, Chunsen Wang, Xuehua Liu, Yuhuan Zheng, Yuping Gong
Rok vydání: 2016
Předmět:
0301 basic medicine
medicine.medical_specialty
congenital
hereditary
and neonatal diseases and abnormalities

Fusion Proteins
bcr-abl

Cystic Fibrosis Transmembrane Conductance Regulator
03 medical and health sciences
0302 clinical medicine
Internal medicine
hemic and lymphatic diseases
medicine
Humans
Philadelphia Chromosome
Protein Phosphatase 2
CFTR
Acute leukemia
Hematology
biology
business.industry
Wnt signaling pathway
Imatinib
Protein phosphatase 2
respiratory system
medicine.disease
Molecular biology
Cystic fibrosis transmembrane conductance regulator
respiratory tract diseases
PP2A
Leukemia
Myeloid
Acute

030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Immunology
biology.protein
business
Ph+ acute leukemia
Chronic myelogenous leukemia
medicine.drug
K562 cells
Signal Transduction
Research Paper
Zdroj: Oncotarget
ISSN: 1949-2553
Popis: // Xi Yang 1, * , Tianyou Yan 1, * , Yuping Gong 1 , Xuehua Liu 1 , Huaqin Sun 2 , Wenming Xu 2 , Chunsen Wang 3 , Duolan Naren 1 , Yuhuan Zheng 1 1 Department of Hematology, West China Hospital, Sichuan University, Chengdu, China 2 Sichuan University-The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Chengdu, China 3 Department of Hematology, Sichuan Provincial People’s Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, China * These authors contributed equally to this work Correspondence to: Yuping Gong, email: gongyuping2010@aliyun.com Keywords: CFTR, Ph + acute leukemia, PP2A Received: May 30, 2016 Accepted: February 06, 2017 Published: February 19, 2017 ABSTRACT Cystic fibrosis transmembrane conductance regulator (CFTR) is classified as an anion channel transporter of Cl − and HCO3 − . Through interactions with its PDZ domain, CFTR is capable of regulating other proteins, such as protein phosphatase 2A (PP2A). The aberrant expression and mutation of CFTR have been observed in several tumor, but not in philadelphia chromosome–positive(Ph + ) acute leukemia, including Ph + B cell acute lymphoblastic leukemia(Ph + B-ALL) and chronic myelogenous leukemia blast crisis phases (CML-BC). In this study, we demonstrated the mean expression level of CFTR in Ph + acute leukemia cells was markedly higher than that in Ph- B-ALL and CML-chronic phase cells. CFTRinh-172, a classic CFTR inhibitor, down-regulated the expression of CFTR, p-BCR-ABL and classical Wnt/β-catenin signaling in Ph + acute leukemia cells, while imatinib had no effect on CFTR. Importantly, reduced efficacy of CFTRinh-172 was closely associated with elevated PP2A phosphatase activity. Furthermore, we confirmed an interaction between CFTR and the PP2AA subunit in K562 cells. In addition, we demonstrated CFTR and PP2AA interact in the cytosol, resulting in PP2 A complex inactivation and increased degradation of PP2 A substrates via the lysosomal/proteasome pathway. In conclusion, our results showed CFTR was highly expressed in Ph + acute leukemia, which protected and maintained the continuous activation of BCR-ABL and the canonical Wnt/β-catenin signaling pathway by decreasing PP2A phosphatase activity. According to this working model of the CFTR-PP2A-BCR-ABL axis, targeting the CFTR protein will activate PP2A and may offer a new treatment strategy for Ph + acute leukemia, especially for patients exhibiting high levels of CFTR expression.
Databáze: OpenAIRE